Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Orthocell Ltd ( (AU:OCC) ) has shared an announcement.
Orthocell Ltd has announced the quotation of 1,367,852 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 10, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for further development and expansion of its regenerative medicine products.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.28 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd operates in the biotechnology industry, focusing on the development and commercialization of regenerative medicine products. The company specializes in treatments that repair and regenerate soft tissue injuries, primarily targeting the orthopedic and dental markets.
Average Trading Volume: 1,414,370
Technical Sentiment Signal: Buy
Current Market Cap: A$308.5M
Find detailed analytics on OCC stock on TipRanks’ Stock Analysis page.